Related Experiment Video
Updated: Jul 18, 2026
A GPC3-targeting Bispecific Antibody, GPC3-S-Fab, with Potent Cytotoxicity
Published on: July 12, 2018
Anti-tumor activity of de novo designed small globular protein (SGP) in vivo
Hitoshi Tsugu1, Hirokazu Onishi, Takeo Fukushima
1Department of Neurosurgery, School of Medicine, Fukuoka University, 45-1, 7-chome Nanakuma Jonan-ku, Fukuoka 814-0180, Japan. h-tsugu@fukuoka-u.ac.jp
Background:
The design and synthesis of a small globular protein (SGP) based on the colicin family of bacteriocins has previously been reported. It has subsequently been shown that this artificial protein possessed cell membrane-disrupting properties. Here, the anti-tumor effects of SGP in subcutaneous nude mice tumor models of human glioma were examined.
Materials And Methods:
Human glioblastoma cells (U-87MG) were transplanted subcutaneously into the backs of nude mice. When tumor volume was between 100 mm(3) and 350 mm(3), tumors were locally injected with SGP three times a week. The four SGP injection groups were 0.5 mM/50 microl, 0.5 mM/100 microl, 1.0 mM/50 microl and 1.0 mM/100 microl (concentration/injection volume). The control group was injected with physiological saline; 100 microl three times a week.
Results:
Tumor volume exhibited a statistically significant decrease (p=0.001) and survival was significantly longer in the SGP-injected groups (p=0.0001). No clear difference in survival time was observed between the 0.5 mM SGP and 1.0 mM SGP groups (p=0.0654). However, the reduction in tumor volume was significantly affected by SGP concentration (p=0.021).
Conclusion:
SGP has an anti-tumor effect in human glioma animal models. The present results also suggest that applied treatment based on local injection of SGP will be effective against deep brain-seated malignant glioma.
